2021
Down-regulation of GP130 signaling sensitizes bladder cancer to cisplatin by impairing Ku70 DNA repair signaling and promoting apoptosis
He S, Li G, Schätzlein AG, Humphrey PA, Weiss RM, Uchegbu IF, Martin DT. Down-regulation of GP130 signaling sensitizes bladder cancer to cisplatin by impairing Ku70 DNA repair signaling and promoting apoptosis. Cellular Signalling 2021, 81: 109931. PMID: 33529758, DOI: 10.1016/j.cellsig.2021.109931.Peer-Reviewed Original ResearchMeSH KeywordsApoptosisCisplatinCytokine Receptor gp130DNA RepairDown-RegulationFemaleGene Expression Regulation, NeoplasticHEK293 CellsHumansKu AutoantigenMaleMCF-7 CellsNeoplasm ProteinsSignal TransductionUrinary Bladder NeoplasmsConceptsBladder cancer cellsCancer cellsHuman bladder cancer specimensCisplatin-based chemotherapyBladder cancer treatmentBladder cancer specimensChemoresistant bladder cancer cellsBreast cancer cellsCell viabilityBladder cancerCancer specimensSmall molecule inhibitorsLevels of Ku70Cancer treatmentKu70 expression
2019
Synergistic inhibition of GP130 and ERK signaling blocks chemoresistant bladder cancer cell growth
Li X, He S, Tian Y, Weiss RM, Martin DT. Synergistic inhibition of GP130 and ERK signaling blocks chemoresistant bladder cancer cell growth. Cellular Signalling 2019, 63: 109381. PMID: 31374291, DOI: 10.1016/j.cellsig.2019.109381.Peer-Reviewed Original ResearchMeSH KeywordsButadienesCarcinoma, Transitional CellCell Line, TumorCell MovementCell SurvivalDrug Resistance, NeoplasmDrug SynergismEnzyme InhibitorsGene Expression Regulation, NeoplasticGlycoproteinsHumansHydrazinesMAP Kinase Signaling SystemMitogen-Activated Protein Kinase 1NitrilesQuinoxalinesUrinary Bladder NeoplasmsConceptsChemoresistant bladder cancerBladder cancer cellsBladder cancerInterleukin-6Clinical outcomesMultidrug resistanceGemcitabine-resistant bladder cancer cellsBladder cancer cell growthMajor treatment obstacleMetastatic bladder cancerPI3K/Akt/mTOR signalingCancer cellsResistant bladder cancer cellsPoor clinical outcomeAkt/mTOR SignalingSynergistic inhibitionNovel therapeutic strategiesPotential therapeutic targetMEK/ERK signalingCancer cell growthRaf/MEK/ERK signalingRole of gp130Therapeutic strategiesTreatment obstaclesTherapeutic targetGlycoprotein-130 expression is associated with aggressive bladder cancer and is a potential therapeutic target
Martin DT, Shen H, Steinbach-Rankins JM, Zhu X, Johnson KK, Syed J, Saltzman WM, Weiss RM. Glycoprotein-130 expression is associated with aggressive bladder cancer and is a potential therapeutic target. Molecular Cancer Therapeutics 2019, 18: molcanther.1079.2017. PMID: 30381445, PMCID: PMC6363894, DOI: 10.1158/1535-7163.mct-17-1079.Peer-Reviewed Original ResearchConceptsBladder cancer cell linesBladder tumorsBladder cancerCancer cell linesHigh-grade bladder cancer cell linesCancer xenograft mouse modelBladder cancer growthAggressive bladder cancerPotential therapeutic targetHuman bladder tumorsXenograft mouse modelBladder cancer progressionCell linesBladder tumor cellsCurative potentialOptimal treatmentTumor gradePatient outcomesReduced cell migrationTumor volumeTumor categoryMouse modelTherapeutic targetTumor aggressivenessCancer growth